Costs

Study says drug development costs much less than previously estimated

Study says drug development costs much less than previously estimated

By

New research suggests that the oft-cited $2.6 billion estimate for bringing a drug to market is significantly overstated.

Five things for pharma marketers to know: Friday, September 8, 2017

Five things for pharma marketers to know: Friday, September 8, 2017

By

Pfizer receives warning letter over EpiPen manufacturing; Opdivo kidney-cancer trial shows improved survival rates; cancer patients who discuss costs with physicians pay less

Five things for pharma marketers to know: Thursday, August 24, 2017

Five things for pharma marketers to know: Thursday, August 24, 2017

By

Amgen publishes study assessing cost-effectiveness of Repatha; Brilinta reduces death in patients with heart-attack history; Roche drug gets priority review

Five things for pharma marketers to know: Monday, August 7, 2017

Five things for pharma marketers to know: Monday, August 7, 2017

By

Insurers deny coverage of generic drugs; Teva to lay off 7,000 employees; Shkreli convicted of securities fraud

Five things for pharma marketers to know: Wednesday, July 19, 2017

Five things for pharma marketers to know: Wednesday, July 19, 2017

By

Cost of throwing out expired drugs is $800 million per year; the FDA approves Gilead's new HCV drug; CDC says 1 in 10 Americans have diabetes

Five things for pharma marketers to know: Friday, June 9, 2017

Five things for pharma marketers to know: Friday, June 9, 2017

By

The FDA asks Endo to take opioid off the market; Lilly partners with Swiss biotech; House committee advances PDUFA bill — without off-label provision

Keep Calm and Sell Drugs: Your New Daily Affirmation?

Keep Calm and Sell Drugs: Your New Daily Affirmation?

By

To be sure, anything borrowing from the well-known "Keep Calm" genre should not be construed as advice. The doctor is definitely not in.

Five things for pharma marketers to know: Thursday, May 4, 2017

Five things for pharma marketers to know: Thursday, May 4, 2017

By

Louisiana may use 1910 law to discount hep-C drugs; House bill would reduce coverage for 24 million people; drugmakers pursue pay-for-performance deals

Five things for pharma marketers to know: Wednesday, April 12, 2017

Five things for pharma marketers to know: Wednesday, April 12, 2017

By

The FDA approves first drug to treat tardive dyskinesia; Americans use crowdfund sites to pay for prescriptions; stroke sufferers struggle with adherence

Sunday at SXSW: Healthcare costs and cancer

Sunday at SXSW: Healthcare costs and cancer

By

A high-profile cancer track commands attention, while wearables and IBM Watson Health come under fire.

Five things for pharma marketers to know: Wednesday, March 8, 2017

Five things for pharma marketers to know: Wednesday, March 8, 2017

By

Researchers question relationship between R&D costs and drug prices; Alexa uses WebMD to answer health questions; lawmakers push GAO to investigate orphan drugs

Why Any Merger is the Last Resort of Lousy Marketers

Why Any Merger is the Last Resort of Lousy Marketers

By

Really? Is this the new healthcare math — the fewer the insurance companies, the greater the competition and the lower the premiums?

Infographic: Type 2 diabetes, a country-by-country snapshot

Infographic: Type 2 diabetes, a country-by-country snapshot

Type 2 diabetes is on the rise, around the world. The IMS Institute for Healthcare Informatics breaks down diabetes prevalence in Brazil, Mexico, Saudi Arabia, the U.K., and the U.S.